Take­da, Abing­worth pro­vide a $100M bankroll for an up­start T cell play­er, build­ing in a buy­out op­tion

Over the past year Take­da has been rip­ping up its old glob­al R&D or­ga­ni­za­tion and cre­at­ing a new one, with a whole new set of col­lab­o­ra­tors. To­day it’s tak­ing a front row seat at a Lon­don-based start­up, pitch­ing in on a $100 mil­lion pack­age to bankroll the con­struc­tion of Gam­maDelta Ther­a­peu­tics’ T cell plat­form while tak­ing an op­tion to ac­quire the biotech.

Things are mov­ing fast at Gam­maDelta, which has some mar­quee Gold­en Tri­an­gle names be­hind it. Take­da and its ven­ture backer Abing­worth are putting in the cash, with Take­da get­ting an eq­ui­ty stake along with its buy­out op­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.